Molecular Details

DICL_CP_0324470 - (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol

Basic Molecular Information

Basic Information

DICL ID

DICL_CP_0324470

PubChem CID

9651

Molecular Formula

C₁₇H₂₁NO₃

Molecular Weight

287.359 g/mol

Synonyms/Alias

[galanthamine; Galantamine; 357-70-0; (-)-Galanthamine; Lycoremin; Lycoremine; Jilkon; Galantamina; Galanthaminum; Galantamin; (-)-Galantamine; Galantaminum; Razadyne; NSC 100058; Galantaminum [INN-La...[galanthamine; Galantamine; 357-70-0; (-)-Galanthamine; Lycoremin; Lycoremine; Jilkon; Galantamina; Galanthaminum; Galantamin; (-)-Galantamine; Galantaminum; Razadyne; NSC 100058; Galantaminum [INN-Latin]; Galantamina [INN-Spanish]; (+/-)-Galantamine; Razadyne ER; Bodamine; BRN 0093736; HSDB 7361; UNII-0D3Q044KCA; 0D3Q044KCA; CHEBI:42944; (+/-)-Galanthamine; Reminyl (TN); Galantamine; (+/-)-; Galanthamine; (+/-)-; CHEMBL659; NSC-100058; (4aS;6R;8aS)-4a;5;9;10;11;12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 23173-12-8; DTXSID2045606; 4-27-00-02184 (Beilstein Handbook Reference); 1T835Z585R; Galantaminum (INN-Latin); Galantamina (INN-Spanish); (1S;12S;14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01;12.06;17]heptadeca-6(17);7;9;15-tetraen-14-ol; 6H-Benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 4a;5;9;10;11;12-hexahydro-3-methoxy-11-methyl-; (4aS;6R;8aS)-; GNT; (1S;12S;14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1;12}.0^{6;17}]heptadeca-6;8;10(17);15-tetraen-14-ol; (4aS;6R;8aS)-3-Methoxy-11-methyl-5;6;9;10;11;12-hexahydro-4aH-benzo[2;3]benzofuro[4;3-cd]azepin-6-ol; (4aS;6R;8aS)-4a;5;9;10;11;12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a;3;2-ef][2]benzazepin-6-ol; 6H-Benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 4a;5;9;10;11;12-hexahydro-3-methoxy-11-methyl-; (4aR;6S;8aR)-rel-; 6H-BENZOFURO(3A;3;2-EF)(2)BENZAZEPIN-6-OL; 4A;5;9;10;11;12-HEXAHYDRO-3-METHOXY-11-METHYL-; (4AS;6R;8AS); 6H-Benzofuro[3a;3;2-ef][2]benzazepin-6-ol; 4a;5;9;10;11;12-hexahydro-3-methoxy-11-methyl-; (4aS;6R;8aS)-; Galantamine (USAN/INN); Galantamine [USAN:INN:BAN]; SR-05000001783; 1qti; Galanthamine; 12; Spectrum_001271; 1dx6; GALANTAMINE [MI]; Prestwick0_000588; Prestwick1_000588; Prestwick2_000588; Prestwick3_000588; Spectrum3_001738; Spectrum4_000839; Spectrum5_001673; GALANTAMINE [INN]; GALANTAMINE [HSDB]; GALANTAMINE [USAN]; Probes1_000055; Probes2_000395; GALANTAMINE [VANDF]; SCHEMBL2577; BSPBio_000436; BSPBio_003416; GALANTAMINE [WHO-DD]; KBioGR_001417; KBioSS_001751; BIDD:GT0517; DivK1c_000590; SPBio_002655; BPBio1_000480; GTPL6693; SCHEMBL3293474; UNII-1T835Z585R; ASUTZQLVASHGKV-JDFRZJQESA-; BDBM10404; KBio1_000590; KBio2_001751; KBio2_004319; KBio2_006887; KBio3_002636; N06DA04; ASUTZQLVASHGKV-JDFRZJQESA-N; NINDS_000590; GLXC-03030; HMS2089H03; HMS3885C10; Pharmakon1600-01501202; MFCD00867189; NSC759861; s3866; AKOS015965330; AM62710; CCG-212961; CS-1217; DB00674; NSC-759861; SDCCGMLS-0066737.P001; IDI1_000590; SMP1_000131; NCGC00017256-05; NCGC00017256-11; NCGC00017256-17; NCGC00024731-02; (4aS;6R;8aS)-4a;5;9;10;11;12-Hexahydro-3-methoxy-11-methyl-6H-benzofurol[3a;3;2;-ef][2]benzazepin-6-ol; 6H-Benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 4a;5;9;10;11;12-hexahydro-3-methoxy-11-methyl-; AC-20240; AC-34328; AS-56354; HY-76299; SBI-0051689.P002; NS00003061; C08526; D04292; EN300-708805; AB00053614-09; AB00053614_10; Q412690; SR-05000001783-4; BRD-K49481516-004-03-5; BRD-K49481516-004-04-3; BRD-K49481516-004-09-2; (1S;12S;14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1;12}.0^{6;17}]heptadeca-6(17);7;9;15-tetraen-14-ol; (4aS;6R;8aS)-3-methoxy-11-methyl-4a;5;9;10;11;12-hexahydro-6H-benzo[2;3]benzofuro[4;3-cd]azepin-6-ol; (4aS;6R;8aS)-3-methoxy-11-methyl-5;6;9;10;11;12-hexahydro-4aH-(1)benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 1008759-59-8; 6H-BENZOFURO(3A;3;2-EF)(2)BENZAZEPIN-6-OL; 4A;5;9;10;11;12-HEXAHYDRO-3-METHOXY-11-METHYL-; (4A.ALPHA.;6.BETA.;8AR*)-; 6H-Benzofuro(3a;3;2-ef)(2)benzazepin-6-ol; 4a;5;9;10;11;12-hexahydro-3-methoxy-11-methyl-; (4aalpha;6beta;8ar*)-; InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6;12;14;19H;7-10H2;1-2H3/t12-;14-;17-/m0/s1]

InChI Key

ASUTZQLVASHGKV-JDFRZJQESA-N

InChI

InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H...

IUPAC Name

(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol

CAS Number

357-70-0

Structure Information

Chemical Structure Visualization

SMILES Notation

2D Molecular Drawing

Carbon (C)

Hydrogen (H)

Oxygen (O)

Nitrogen (N)

Sulfur (S)

SDF

42 45 0 0 0 0 0 0 0 0999 V2000
-3.7886 -1.3140 -1.0730 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5055 -0.8872 -0.4900 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.7576 0.080...

Download SDF File (3602 bytes)

Experimental Data

Activity Data

Target Ion Channel

Voltage-gated potassium channel subfamily B member 1

Uniprot Accession Number

Q14721

Function

Agonist

Species

Homo sapiens (Human)

IC₅₀

N/A (Not available)

EC₅₀

EC₅₀: 5600 nM

K_i

N/A (Not available)

K_d

N/A (Not available)

Inhibition

N/A (Not available)

Experimental Conditions

pH 7.4

Holding Potential

−50 mV mV

Temperature

21−23 °C

Test Method

Patch-clamping

Test Species

HEK293 cell (Homo sapiens embryonic kidney 293 cell)

Binding Information

Binding Site

Not specified

Binding Site Residue

Not specified

Disease Information

Related Disease

Not specified

References

DOI

10.1016/j.molbrainres.2004.08.010

URL

N/A (Not available)

PMID

15530663

Patent

N/A (Not available)

Computed Properties

Heavy Atom Count

Rotatable Bonds

logP

1.8503

Complexity

79.8028

TPSA (Å²)

41.93

H-Bond Donors

H-Bond Acceptors

Ring Count

New Search